"Omics" data and levels of evidence for biomarker discovery

Genomics

Volumn 93, Issue 1, 2009, Pages 13-16

  Ghosh, Debashis ^a   Poisson, Laila M ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomarker; Cancer; Gene Expression; High dimensional data; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ASSAY; BREAST CANCER; HUMAN; NEOPLASM; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; HUMANS; NEOPLASMS; PROTEOMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 57049122827     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2008.07.006     Document Type: Article

References (27)

1. Burzykowski T., Molenberghs G., and Buyse M. The Evaluation of Surrogate Endpoints (2005), Springer-Verlag, Berlin/New York
2. Slotnick M.J., and Nriagu J.O. Validity of human nails as a biomarker of arsenic and selenium exposure: a review. Environ. Res. 102 (2006) 125-139
3. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., Radich J., Anderson G., and Hartwell L. The case for early detection. Nat. Rev. Cancer 3 (2003) 243-252
4. Hayes D.F. Prognostic and predictive factors revisited. Breast 14 (2005) 493-499
5. Biomarkers Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69 (2001) 89-95
6. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23 (2005) 9067-9072
7. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff - In Vitro Diagnostic Multivariate Index Assays. U.S. Food and Drug Administration. Web site: http://www.fda.gov/cdrh/ovid/guidance/1610.html. August 25, 2008.
8. Kriete A., Sokhansanj B.A., Coppock D.L., and West G.B. Systems approaches to the networks of aging. Ageing Res. Rev. 5 (2006) 434-448
9. Hastie T., Tibshirani R., and Friedman J.H. The Elements of Statistical Learning (2001), Springer, New York
10. Jain A.K., and Dubes R.C. Algorithms for Clustering Data (1988), Prentice Hall, New York
11. Miller R.G. Simultaneous Statistical Inference. (2nd ed.) (1981), Springer-Verlag, New York
12. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., B. 57 (1995) 289-300
13. Abecasis G.R., Ghosh D., and Nichols T.E. Linkage disequilibrium: ancient history drives the new genetics. Hum. Hered. 59 (2005) 118-124
14. West M. Bayesian factor regression models in the "large p, small n" paradigm. Bayesian Stat. 7 (2003) 723-732
15. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S.A., Nobel A.B., van't Veer L.J., and Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006) 560-569
16. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
17. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
18. MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy) A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer. (EORTC Protocol 10041 - BIG 3-04). Web site: http://www.eortc.be/services/unit/mindact/documents/MINDACT_trial_outline.pdf. Date: August 25, 2008.
19. National Cancer Institute : The TAILORx Breast Cancer Trial. Web site: http://www.cancer.gov/clinicaltrials/digestpage/TAILORx. Date: August 25, 2008.
20. Ghosh D., and Chinnaiyan A.M. Covariate adjustment in the analysis of microarray data from clinical studies. Funct. Integr. Genomics 5 (2005) 18-27
21. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5 (2005) 142-149
22. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8 (2002) 816-824
23. Bhattacharjee A., Richards W.G., Staunton J., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13790-13795
24. Rhodes D., Barrette T.R., Rubin M.A., et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 62 (2002) 4427-4433
25. Shen R., Ghosh D., and Chinnaiyan A.M. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics 5 (2005) 94
26. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93 (2001) 1054-1061
27. Levels of evidence, BJU Int. 101 (2008) 150, doi:10.1111/j.1464-410x.2007.07384.x.